NCT01922089
Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients
Sponsored by Novartis Pharmaceuticals
The purpose of this study is to assess the safety and tolerability of initiating LCZ696 in heart failure patients with reduced ejection fraction (HF-rEF) using conservative (reaching target dose over 6 weeks) and condensed (reaching target dose over 3 weeks) up-titration regimens.
Inclusion Criteria: * Age ≥ 18 years; CHF with New York Heart Association class II-IV; left ventricular ejection fraction ≤ 35%; on beta blockers Exclusion Criteria: * Potassium \> 5.2 mmol/l; estimated glomerular filtration rate \< 30 ml/min/1.73 m2; systolic blood pressure \<100 mmHg or \> 180 mmHg; history of intolerance to recommended target doses of angiotensin converting enzyme inhibitors or angiotensin receptor blockers Other protocol-defined inclusion/exclusion criteria may apply.
Novartis Investigative Site
Anchorage, Alaska, United States
Novartis Investigative Site
Gilbert, Arizona, United States
Novartis Investigative Site
Tucson, Arizona, United States
Novartis Investigative Site
Anaheim, California, United States
Novartis Investigative Site
Torrance, California, United States
Novartis Investigative Site
Atlantis, Florida, United States
Novartis Investigative Site
Chiefland, Florida, United States
Novartis Investigative Site
Aurora, Illinois, United States
Novartis Investigative Site
Peoria, Illinois, United States
Novartis Investigative Site
Evansville, Indiana, United States
Novartis Investigative Site
Slidell, Louisiana, United States
Novartis Investigative Site
Minneapolis, Minnesota, United States
Novartis Investigative Site
St Louis, Missouri, United States
Novartis Investigative Site
Buffalo, New York, United States
Novartis Investigative Site
Laurelton, New York, United States
Novartis Investigative Site
Marion, Ohio, United States
Novartis Investigative Site
Oak Ridge, Tennessee, United States
Novartis Investigative Site
Dallas, Texas, United States
Novartis Investigative Site
Houston, Texas, United States
Novartis Investigative Site
Houston, Texas, United States
Novartis Investigative Site
Livingston, Texas, United States
Novartis Investigative Site
Tacoma, Washington, United States
Novartis Investigative Site
Gabrovo, Bulgaria, Bulgaria
Novartis Investigative Site
Plovdiv, Bulgaria, Bulgaria
Novartis Investigative Site
Plovdiv, Bulgaria, Bulgaria
Novartis Investigative Site
Smolyan, Bulgaria, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Jyväskylä, Finland
Novartis Investigative Site
Tampere, Finland
Novartis Investigative Site
Bad Krozingen, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Buch, Germany
Novartis Investigative Site
Dietzenbach, Germany
Novartis Investigative Site
Ebersbach, Germany
Novartis Investigative Site
Frankfurt, Germany
Novartis Investigative Site
Göttingen, Germany
Novartis Investigative Site
Haßloch, Germany
Novartis Investigative Site
Huy / OT Anderbeck, Germany
Novartis Investigative Site
Ingelheim, Germany
Novartis Investigative Site
Kelkheim, Germany
Novartis Investigative Site
Kleve, Germany
Novartis Investigative Site
Leipzig, Germany
Novartis Investigative Site
Mainz, Germany
Novartis Investigative Site
Mainz, Germany
Novartis Investigative Site
Mühlheim, Germany
Novartis Investigative Site
Siegen, Germany
Novartis Investigative Site
Straubing, Germany
Novartis Investigative Site
Würzburg, Germany
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Debrecen, Hungary
Novartis Investigative Site
Mosonmagyaróvár, Hungary
Novartis Investigative Site
Nyiregyháza, Hungary
Novartis Investigative Site
Pécs, Hungary
Novartis Investigative Site
Székesfehérvár, Hungary
Novartis Investigative Site
Aosta, AO, Italy
Novartis Investigative Site
Cortona, AR, Italy
Novartis Investigative Site
Bergamo, BG, Italy
Novartis Investigative Site
Bologna, BO, Italy
Novartis Investigative Site
Cona, FE, Italy
Novartis Investigative Site
Albano Laziale, RM, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Sassari, SS, Italy
Novartis Investigative Site
Vittorio Veneto, TV, Italy
Novartis Investigative Site
San Daniele del Friuli, UD, Italy
Novartis Investigative Site
San Juan, Puerto Rico
Novartis Investigative Site
Brezno, Slovak Republic, Slovakia
Novartis Investigative Site
Nitra, Slovak Republic, Slovakia
Novartis Investigative Site
Svidník, Slovak Republic, Slovakia
Novartis Investigative Site
Bratislava, Slovakia, Slovakia
Novartis Investigative Site
Bratislava, Slovakia, Slovakia
Novartis Investigative Site
Košice, Slovakia, Slovakia
Novartis Investigative Site
Lučenec, Slovakia, Slovakia
Novartis Investigative Site
Nové Zámky, Slovakia, Slovakia
Novartis Investigative Site
Trebišov, Slovakia, Slovakia
Novartis Investigative Site
Almería, Andalusia, Spain
Novartis Investigative Site
Málaga, Andalusia, Spain
Novartis Investigative Site
Sanlúcar de Barrameda, Andalusia, Spain
Novartis Investigative Site
Seville, Andalusia, Spain
Novartis Investigative Site
Villamartín, Cadiz, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
A Coruña, Galicia, Spain
Novartis Investigative Site
Madrid, Madrid, Spain
Novartis Investigative Site
Istanbul, Turkey, Turkey (Türkiye)
Novartis Investigative Site
Haydarpasa/Istanbul, Turkey (Türkiye)
Novartis Investigative Site
Kocaeli, Turkey (Türkiye)
Novartis Investigative Site
Mersin, Turkey (Türkiye)
Novartis Investigative Site
Sivas, Turkey (Türkiye)
Novartis Investigative Site
Dorchester, Dorset, United Kingdom
Novartis Investigative Site
Saint Leonards-on-Sea, East Sussex, United Kingdom
Novartis Investigative Site
Oldham, Lancashire, United Kingdom
Novartis Investigative Site
Gateshead, Tyne and Wear, United Kingdom
Novartis Investigative Site
Bath, United Kingdom
Novartis Investigative Site
Bradford, United Kingdom
Novartis Investigative Site
Coventry, United Kingdom
Novartis Investigative Site
Harrow, United Kingdom
Novartis Investigative Site
Nuneaton, United Kingdom
Identity-resolution confidence concerns registry/entity resolution and does not determine clinical eligibility.
Interested in this trial?
Express your interest and we'll connect you with the trial team.
Your selected profile and contact information may be shared with an authorised trial site, sponsor, or Clintriva coordination team for trial contact and pre-screening. Expressing interest does not mean you are eligible or enrolled.
Conditions